Generic Medicine Info
Indications and Dosage
Gastrointestinal tract spasm, Irritable bowel syndrome
Adult: 135 mg tid, may reduce gradually after several wk when the desired effect has been obtained; 100 mg tid has also been used. As modified-release cap: 200 mg bid.
Paralytic ileus.
Special Precautions
Patient w/ cardiac disorders (e.g. heart block). Renal and hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Dizziness, headache, GI disturbances, insomnia, anorexia, decreased heart rate, hypersensitivity (e.g. urticaria, erythematous rash, angioedema).
Symptoms: CNS excitability. Management: Symptomatic and supportive treatment. Gastric lavage may be considered in case of multiple intoxication or if discovered w/in approx 1 hr.
Description: Mebeverine is an antispasmodic agent which exerts direct action on the GI smooth muscle w/o affecting normal gut motility. The exact mechanism is unknown, but multiple mechanisms might contribute to its local effect in the GI tract, e.g. a decrease in ion channel permeabilities, blockade of norepinephrine reuptake, a local anaesth effect, changes in water absorption and weak anti-muscarinergic and phosphodiesterase inhibitory effect.
Absorption: Rapidly absorbed from the GI tract. Time to peak plasma concentration: 1-3 hr.
Distribution: Plasma protein-binding: 75% to albumin.
Metabolism: Completely metabolised via hydrolysis to form veratric acid and mebeverine alcohol.
Excretion: Via urine (95% as metabolites).
Store below 30°C.
MIMS Class
ATC Classification
A03AA04 - mebeverine ; Belongs to the class of synthetic anticholinergics, esters with tertiary amino group. Used in the treatment of functional bowel disorders.
Anon. Mebeverine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 15/01/2016.

Buckingham R (ed). Mebeverine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 15/01/2016.

Joint Formulary Committee. Mebeverine Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 15/01/2016.

Disclaimer: This information is independently developed by MIMS based on Mebeverine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
  • Lezpain
  • Mebetin
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in